TSE:HBP

Helix BioPharma (HBP) Stock Forecast, Price & News

C$0.24

0.00 (0.00%)

(As of 09/22/2023 ET)

Compare

Today's Range: C$0.24
▼
C$0.24
50-Day Range: C$0.21
▼
C$0.25
52-Week Range: C$0.19
▼
C$0.26

Volume: 17,100 shs
Average Volume: 5,323 shs
Market Capitalization: C$52.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Earnings Headlines Options Chain Social Media

About Helix BioPharma (TSE:HBP) Stock

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

HBP Price History

30 days | 90 days | 365 days | Advanced Chart

HBP Stock News Headlines

August 22, 2023 | stockhouse.com

Helix BioPharma Corp. Announces Closing of Private Placement of CAD $3 Million and Board Changes

June 14, 2023 | msn.com

Helix Biopharma GAAP EPS of -C$0.01

September 23, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

June 14, 2023 | finance.yahoo.com

Helix BioPharma Corp. Announces Fiscal 2023 Third Quarter Results

November 1, 2022 | proactiveinvestors.com

Helix BioPharma advances clinical development of lead candidate L-DOS47, but manages to decrease R&D expenses in 2022 fiscal year

November 1, 2022 | finance.yahoo.com

HELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End Results

September 2, 2022 | proactiveinvestors.com

Helix BioPharma Corp names Dr Gabrielle Siegers as its head of research and development

September 2, 2022 | proactiveinvestors.com

Helix BioPharma names Dr Gabrielle Siegers as head of research and development

September 23, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 1, 2022 | finance.yahoo.com

Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development

August 30, 2022 | finance.yahoo.com

Helix Biopharma Corp. Announces Conclusion of Funding Agreement with Lind Global Macro Fund LP

June 14, 2022 | finance.yahoo.com

HELIX BIOPHARMA Corp. Announces Fiscal 2022 Third Quarter Results

June 3, 2022 | finance.yahoo.com

Helix Biopharma Corp. Announces Closure of Early Warrant Exercise Incentive Program | Raises Aggregate $3.21 Million

May 17, 2022 | finance.yahoo.com

Insiders may be rethinking their CA$3.0m Helix BioPharma Corp. (TSE:HBP) investment now that the company has lost CA$5.0m in value

April 22, 2022 | finance.yahoo.com

Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.

April 18, 2022 | finanznachrichten.de

Helix BioPharma Corp.: Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

April 18, 2022 | finance.yahoo.com

Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

April 7, 2022 | finanznachrichten.de

Helix BioPharma Corp.: Helix Announces Board Resignation

March 22, 2022 | finanznachrichten.de

Helix BioPharma Corp.: Helix Biopharma Corp. Announces Management and Board Changes

March 22, 2022 | finance.yahoo.com

Helix Biopharma Corp. Announces Management and Board Changes

March 16, 2022 | finanznachrichten.de

Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

March 16, 2022 | proactiveinvestors.com

Helix BioPharma announces sudden passing of interim CEO Slawomir Majewski

March 11, 2022 | apnews.com

Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

March 11, 2022 | finance.yahoo.com

CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

March 11, 2022 | finance.yahoo.com

Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

December 31, 2021 | ca.finance.yahoo.com

Stocks in play: Helix BioPharma Corp

December 15, 2021 | finanznachrichten.de

Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

See More Headlines

Receive HBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HBP Company Calendar

Today: 9/23/2023
Next Earnings (Estimated): 10/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:HBP
CUSIP: N/A
CIK: N/A
Web: www.helixbiopharma.com
Phone: +1-416-9253232
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-5,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -168.99%

Debt

Debt-to-Equity Ratio: 773.67
Current Ratio: 2.30
Quick Ratio: 1.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 216,670,000
Free Float: N/A
Market Cap: C$52.00 million
Optionable: Optionable
Beta: -0.50

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Jacek Antas
CEO & Director

Mr. Hatem Kawar M.B.A. (Age 64)
MBA, P.Eng, P.Eng., Chief Financial Officer

Dr. Gabrielle M. Siegers M.A.
Ph.D., Head of R&D

Ms. Namrata Malhotra
Corp. Sec.

Key Competitors

View All Competitors

HBP Stock - Frequently Asked Questions

How have HBP shares performed in 2023?: Helix BioPharma's stock was trading at C$0.22 at the beginning of the year. Since then, HBP shares have increased by 11.6% and is now trading at C$0.24.
View the best growth stocks for 2023 here.
When is Helix BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our HBP earnings forecast.
What other stocks do shareholders of Helix BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Helix BioPharma investors own include Lakeland Industries (LAKE), Liquidia (LQDA), Ovintiv (OVV), SIG (SHI), Green Organic Dutchman (TGOD), Zynerba Pharmaceuticals (ZYNE), American Airlines Group (AAL), Aurora Cannabis (ACB), Apollo Investment (AINV) and Aphria (APHA).
What is Helix BioPharma's stock symbol?: Helix BioPharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HBP."

How do I buy shares of Helix BioPharma?: Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Helix BioPharma's stock price today?: One share of HBP stock can currently be purchased for approximately C$0.24.
How much money does Helix BioPharma make?: Helix BioPharma (TSE:HBP) has a market capitalization of C$52.00 million. The biopharmaceutical company earns C$-5,520,000.00 in net income (profit) each year or C($0.02) on an earnings per share basis.
How can I contact Helix BioPharma?: Helix BioPharma's mailing address is 21 St Clair Ave E Suite 1100, TORONTO, ON M4T 1L9, Canada. The official website for the company is www.helixbiopharma.com. The biopharmaceutical company can be reached via phone at +1-416-9253232.

This page (TSE:HBP) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial